Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC
The US Food and Drug Administration (FDA) is scheduled to review an application submitted by...
Cancer
MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study...
Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China
Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical...
HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Gastric Cancer
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its MET inhibitor, Orpathys (savolitinib),...
CytoMed Therapeutics Partners with CNK Therapeutics for CAR Gene Grafting Technology
Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a...
CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC
Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the...
Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies
Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix...
J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment
The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...
Medivir’s Fostrox in Combination with Lenvima Shows Promise in Phase IIa HCC Trial
Sweden-based Medivir (STO: MVIR) has released interim data from a Phase IIa trial evaluating the...
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...
Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China
Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical...
Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006...
Medtronic Partners with APMG to Advance Orthopedic Treatment Services in China
US-based Medtronic Inc., (NYSE: MDT) has entered into a partnership with China’s private healthcare group...
NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma
The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...
Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...